Etoricoxib, a commonly prescribed non-steroidal anti-inflammatory drug (NSAID), has been associated with adverse cutaneous reactions, including fixed drug eruption (FDE). We describe a case report of a 37-year-old Thai male who developed erythematous plaques and bullous lesions following the ingestion of a 90 mg dose of Etoricoxib. The lesions were located on the lateral aspect of the right leg near the popliteal fossa, the dorsal aspect of the right foot, the medial aspect of the right arm, and the left lumbar region.
View Article and Find Full Text PDF